Physician profile
Ajit Nemi
NPI 1932130671
$5,189.77
in general payments reported to CMS, 2019-2025
32 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $406 · 2021: $429 · 2022: $614 · 2023: $1,060 · 2024: $498 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120 · Honoraria: $53.37 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,120.44 |
| Honoraria | $53.37 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $886.80 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $476.63 | 2019-2024 | Tecnis Simplicity, Tecnis Iol |
| Abbvie INC. | $416.49 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $264.05 | 2019-2021 | |
| Eyepoint US, INC. | $250.00 | 2019 | |
| Oyster Point Pharma, INC. | $246.23 | 2022-2025 | Tyrvaya |
| Rxsight INC | $198.75 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Ivantis, INC | $183.07 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $181.04 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Sight Sciences, INC. | $169.44 | 2021-2023 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $165.67 | 2020-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $150.43 | 2019 | |
| Shire North American Group INC | $148.95 | 2019 | |
| Dompe US, INC. | $146.67 | 2022-2023 | Oxervate |
| Glaukos Corporation | $145.92 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $132.10 | 2019 | |
| Alimera Sciences, INC. | $127.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $123.30 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $112.39 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $110.28 | 2021 | |
| Horizon Therapeutics Plc | $103.12 | 2022 | |
| Allergan, INC. | $97.36 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $79.56 | 2019-2022 | |
| Harrow Eye, LLC | $62.33 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $58.25 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $46.76 | 2019-2024 | |
| Astellas Pharma US INC | $21.53 | 2024 | Izervay |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $18.45 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $18.42 | 2019 | |
| Glaxosmithkline, LLC. | $16.17 | 2025 | Blenrep |
| Akorn Operating Company LLC | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajit Nemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.